New Orleans Center for Clinical Research Report issue

For profit Phase 1 Phase 2
Founded: New Orleans LA United States (1985)
Status: Acquired by Alliance for Multispecialty Research (2017)

Organization Overview

First Clinical Trial
1997
NCT01674192
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

New Orleans Center for Clinical Research, 2820 Canal Street, New Orleans, LA 70119 | New Orleans Center for Clinical Research-Knoxville | New Orleans Center for Clinical Research- Knoxville | New Orleans Center for Clinical Research (NOCCR) | New Orleans Clinical Center for Research | Volunteer Research Group and New Orleans Center for Clinical Research

Active Ingredients

Drugs in Phase 2 Trials (1)

sitagliptin (januvia) (1 trial)

Drugs in Phase 1 Trials (6)

avi-6002 (1 trial)

diclofenac (voltaren) (1 trial)

eravacycline (Xerava) (1 trial)

itraconazole (sporanox) (1 trial)

prucalopride (1 trial)

vasomera (1 trial)

Drugs in Other Trials (2)

sodium bicarbonate (1 trial)

thiram (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Constipation (Phase 1)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Essential Hypertension (Phase 1)

Hemorrhagic Fever, Ebola (Phase 1)

Hemorrhagic Fevers, Viral (Phase 1)

Hepatic Insufficiency (Phase 1)

Hypertension (Phase 1)

Liver Failure (Phase 1)

Renal Insufficiency (Phase 1)

Renal Insufficiency, Chronic (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 9